Abstract：【Objective】To investigate the clinical efficacy of Sulodexide combined with epalrestat in the treatment of type 2 diabetesmellitus (T2DM) patients with diabetic peripheral neuropathy (DPN).【Methods】A total of 95 T2DM patients with DPN treated in our hospital from February 2020 to March 2023 were selected and divided into control group (receiving epalrestat treatment, n=46) and observation group (receiving Sulodexide treatment on the basis of control group treatment, n=49) according to different treatment methods. The clinical efficacy, clinical score, nerve conduction velocity, glycated hemoglobin(HbA1c), fasting blood glucose (FPG), serological indexes and incidence of adverse reactions were compared between the two groups.【Results】The total effective rate of the observation group was higher than that of the control group (P<0.05). After treatment, the pain, paresthesia, burning sensation, numbness scores and serum malondialdehyde (MDA) and endothelin-1 (ET-1) levels in both groups were lower than before treatment (P<0.05), and the pain, paresthesia, burning sensation, numbness scores and serum MDA and ET-1 levels in the observation group were lower than those in the control group (P<0.05). After treatment, the sensory conduction velocity (SNCV), motor conduction velocity (MNCV) and serum nitric oxide (NO) levels of the median nerve and common peroneal nerve in both groups were higher than before treatment (P<0.05), and the levels of SNCV, MNCV and NO in the median nerve and common peroneal nerve in the observation group were higher than those in the control group (P<0.05). After treatment, the HbA1c and FPG of both groups were lower than before treatment (P<0.05), and the HbA1c and FPG of observation group were lower than those of control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).【Conclusion】Sulodexide combined with epalrestat is effective in the treatment of T2DM patients with DPN, and can improve blood glucose control, clinical symptoms, oxidative stress index, vascular endothelial function index, nerve conduction velocity, and is safe and reliable.
吴昌昊. 舒洛地特联合依帕司他治疗2型糖尿病合并糖尿病周围神经病变的临床疗效[J]. 医学临床研究, 2024, 41(11): 1715-1718.
WU Changhao. Clinical Efficacy of Sulodexide Combined with Epalrestat in the Treatment of Type 2 Diabetes Mellitus Complicated with Diabetic Peripheral Neuropathy. JOURNAL OF CLINICAL RESEARCH, 2024, 41(11): 1715-1718.
2024, Vol. 41 
